Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Cardiac Sarcoidosis
NCT06868381Phase 2Not yet recruiting
- Sponsor
- Stanford University
- Start
- Apr 2026
- Primary completion
- Jul 2028
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in cardiac sarcoidosis (CS), sponsored by Stanford University. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
baricitinib
03
Conditions
cardiac sarcoidosis (CS)
Beyond the preview
Go deeper on NCT06868381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06868381.